{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:56:23Z","timestamp":1782842183153,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06684"],"award-info":[{"award-number":["21K06684"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11096-024-01810-1","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T13:01:50Z","timestamp":1728046910000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study"],"prefix":"10.1007","volume":"47","author":[{"given":"Yuki","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-0785","authenticated-orcid":false,"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"6","key":"1810_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.curtheres.2012.07.002","volume":"73","author":"C Chen","year":"2012","unstructured":"Chen C, Guo DH, Cao X, et al. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195\u2013206. https:\/\/doi.org\/10.1016\/j.curtheres.2012.07.002.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"1810_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s10096-013-2041-3","volume":"33","author":"HY Dong","year":"2014","unstructured":"Dong HY, Xie J, Chen LH, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33(6):1029\u201335. https:\/\/doi.org\/10.1007\/s10096-013-2041-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"1810_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2006.04.017","volume":"28","author":"YH Lin","year":"2006","unstructured":"Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345\u201351. https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.04.017.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"1810_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s10096-017-2960-5","volume":"36","author":"J Gonz\u00e1lez-Del Castillo","year":"2017","unstructured":"Gonz\u00e1lez-Del Castillo J, Candel FJ, Manzano-Lorenzo R, et al. Predictive score of haematological toxicity in patients treated with linezolid. Eur J Clin Microbiol Infect Dis. 2017;36(8):1511\u20137. https:\/\/doi.org\/10.1007\/s10096-017-2960-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"1810_CR5","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1038\/s41598-022-13874-y","volume":"12","author":"YC Hsu","year":"2022","unstructured":"Hsu YC, Chen SY, Hung YJ, et al. Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients. Sci Rep. 2022;12(1):9894. https:\/\/doi.org\/10.1038\/s41598-022-13874-y.","journal-title":"Sci Rep"},{"issue":"3","key":"1810_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00228-023-03455-x","volume":"79","author":"Y Inoue","year":"2023","unstructured":"Inoue Y, Takekuma Y, Miyai T, et al. Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia. Eur J Clin Pharmacol. 2023;79(3):415\u201325. https:\/\/doi.org\/10.1007\/s00228-023-03455-x.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1810_CR7","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkt133","volume":"68","author":"Y Nukui","year":"2013","unstructured":"Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128\u201333. https:\/\/doi.org\/10.1093\/jac\/dkt133.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1810_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1086\/498509","volume":"42","author":"VC Wu","year":"2006","unstructured":"Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66\u201372. https:\/\/doi.org\/10.1086\/498509.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1810_CR9","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/jac\/dks153","volume":"67","author":"F Pea","year":"2012","unstructured":"Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034\u201342. https:\/\/doi.org\/10.1093\/jac\/dks153.","journal-title":"J Antimicrob Chemother"},{"key":"1810_CR10","doi-asserted-by":"publisher","first-page":"967311","DOI":"10.3389\/fpubh.2022.967311","volume":"10","author":"B Lin","year":"2022","unstructured":"Lin B, Hu Y, Xu P, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022;10:967311. https:\/\/doi.org\/10.3389\/fpubh.2022.967311.","journal-title":"Front Public Health"},{"issue":"3","key":"1810_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","volume":"44","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44(3):242\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.010.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1810_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40360-021-00479-w","volume":"22","author":"H Kawasuji","year":"2021","unstructured":"Kawasuji H, Tsuji Y, Ogami C, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol. 2021;22(1):13. https:\/\/doi.org\/10.1186\/s40360-021-00479-w.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"6","key":"1810_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","volume":"41","author":"D Cattaneo","year":"2013","unstructured":"Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.02.020.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"1810_CR14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10156-010-0182-1","volume":"17","author":"Y Takahashi","year":"2011","unstructured":"Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382\u20137. https:\/\/doi.org\/10.1007\/s10156-010-0182-1.","journal-title":"J Infect Chemother"},{"issue":"8","key":"1810_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","volume":"22","author":"Y Hanai","year":"2016","unstructured":"Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22(8):536\u201342. https:\/\/doi.org\/10.1016\/j.jiac.2016.05.003.","journal-title":"J Infect Chemother"},{"issue":"2","key":"1810_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/jcpt.13287","volume":"46","author":"R Tanaka","year":"2021","unstructured":"Tanaka R, Suzuki Y, Morinaga Y, et al. A retrospective test for a possible relationship between linezolid-induced thrombocytopenia and hyponatraemia. J Clin Pharm Ther. 2021;46(2):343\u201351. https:\/\/doi.org\/10.1111\/jcpt.13287.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"1810_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jcpt.12260","volume":"40","author":"T Ichie","year":"2015","unstructured":"Ichie T, Suzuki D, Yasui K, et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther. 2015;40(3):279\u201384. https:\/\/doi.org\/10.1111\/jcpt.12260.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"1810_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s15010-014-0674-5","volume":"42","author":"B Natsumoto","year":"2014","unstructured":"Natsumoto B, Yokota K, Omata F, et al. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007\u201312. https:\/\/doi.org\/10.1007\/s15010-014-0674-5.","journal-title":"Infection"},{"issue":"12","key":"1810_CR19","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1111\/jcpt.13747","volume":"47","author":"T Onita","year":"2022","unstructured":"Onita T, Ishihara N, Ikebuchi A, et al. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia. J Clin Pharm Ther. 2022;47(12):2041\u20138. https:\/\/doi.org\/10.1111\/jcpt.13747.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"1810_CR20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-023-03542-z","volume":"79","author":"D Zhang","year":"2023","unstructured":"Zhang D, Xu Y, Wang X, et al. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2023;79(10):1303\u201314. https:\/\/doi.org\/10.1007\/s00228-023-03542-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1810_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"1810_CR22","unstructured":"SWOG. Cancer Research Network \u2013 Cancer Research and Biostatistics. https:\/\/stattools.crab.org\/Calculators\/twoArmNormal.htm, Accessed 26.08.2024."},{"issue":"3","key":"1810_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.eimc.2015.06.012","volume":"34","author":"D Echeverr\u00eda-Esnal","year":"2016","unstructured":"Echeverr\u00eda-Esnal D, Retamero A, Pardos SL, et al. Severe thrombocytopenia caused by linezolid poisoning in an underweight critically ill patient with renal impairment treated with the recommended doses. Enferm Infecc Microbiol Clin. 2016;34(3):213\u20134. https:\/\/doi.org\/10.1016\/j.eimc.2015.06.012.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"34","key":"1810_CR24","doi-asserted-by":"publisher","first-page":"e11997","DOI":"10.1097\/MD.0000000000011997","volume":"97","author":"MG Wang","year":"2018","unstructured":"Wang MG, Wang D, He JQ. Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: a case report. Med (Baltim). 2018;97(34):e11997. https:\/\/doi.org\/10.1097\/MD.0000000000011997.","journal-title":"Med (Baltim)"},{"key":"1810_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.12659\/AJCR.911362","volume":"19","author":"B Xiao","year":"2018","unstructured":"Xiao B, Deng P, Jin H, et al. Lactic acidosis and Thrombocytopenia Associated with Linezolid Therapy: a Case Report. Am J Case Rep. 2018;19:1117\u201320. https:\/\/doi.org\/10.12659\/AJCR.911362.","journal-title":"Am J Case Rep"},{"issue":"4","key":"1810_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-014-9961-6","volume":"36","author":"R Hirano","year":"2014","unstructured":"Hirano R, Sakamoto Y, Tachibana N, et al. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36(4):795\u20139. https:\/\/doi.org\/10.1007\/s11096-014-9961-6.","journal-title":"Int J Clin Pharm"},{"issue":"11","key":"1810_CR27","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1177\/1060028018783498","volume":"52","author":"AD Rabon","year":"2018","unstructured":"Rabon AD, Fisher JP, MacVane SH. Incidence and risk factors for development of Thrombocytopenia in patients treated with linezolid for 7 days or Greater. Ann Pharmacother. 2018;52(11):1162\u20134. https:\/\/doi.org\/10.1177\/1060028018783498.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1810_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/jcpt.13359","volume":"46","author":"Y Dai","year":"2021","unstructured":"Dai Y, Jiang S, Chen X, et al. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients. J Clin Pharm Ther. 2021;46(3):807\u201313. https:\/\/doi.org\/10.1111\/jcpt.13359.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1810_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bcp.14965","volume":"88","author":"C Shi","year":"2022","unstructured":"Shi C, Xia J, Ye J, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):464\u201375. https:\/\/doi.org\/10.1111\/bcp.14965.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1810_CR30","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/0091270009337947","volume":"49","author":"S Abe","year":"2009","unstructured":"Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49(9):1071\u20138. https:\/\/doi.org\/10.1177\/0091270009337947.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1810_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/bcpt.13123","volume":"124","author":"GW Choi","year":"2019","unstructured":"Choi GW, Lee JY, Chang MJ, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228\u201334. https:\/\/doi.org\/10.1111\/bcpt.13123.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"1810_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40268-024-00458-6","volume":"24","author":"SRE Laarhuis","year":"2024","unstructured":"Laarhuis SRE, Kerskes CHM, Nijziel MR, et al. Linezolid-Induced Thrombocytopenia in patients with renal impairment: a Case Series, Review and Dose advice. Drugs R D. 2024;24(1):109\u201315. https:\/\/doi.org\/10.1007\/s40268-024-00458-6.","journal-title":"Drugs R D"},{"issue":"8","key":"1810_CR33","doi-asserted-by":"publisher","first-page":"e00605","DOI":"10.1128\/AAC.00605-19","volume":"63","author":"RL Crass","year":"2019","unstructured":"Crass RL, Cojutti PG, Pai MP, et al. Reappraisal of Linezolid Dosing in Renal Impairment to improve Safety. Antimicrob Agents Chemother. 2019;63(8):e00605\u201319. https:\/\/doi.org\/10.1128\/AAC.00605-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1810_CR34","doi-asserted-by":"publisher","first-page":"112968","DOI":"10.1016\/j.jpba.2019.112968","volume":"178","author":"E Souza","year":"2020","unstructured":"Souza E, Felton J, Crass RL, et al. Development of a sensitive LC-MS\/MS method for quantification of linezolid and its primary metabolites in human serum. J Pharm Biomed Anal. 2020;178:112968. https:\/\/doi.org\/10.1016\/j.jpba.2019.112968.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"1810_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.18999\/nagjms.82.3.407e","volume":"82","author":"Y Sato","year":"2020","unstructured":"Sato Y, Iguchi M, Kato Y, et al. Number of concomitant drugs with thrombocytopenic adverse effects and the extent inflammatory response resolution are risk factors for thrombocytopenia in patients treated with linezolid for more than 14 days. Nagoya J Med Sci. 2020;82(3):407\u201314. https:\/\/doi.org\/10.18999\/nagjms.82.3.407.","journal-title":"Nagoya J Med Sci"},{"key":"1810_CR36","doi-asserted-by":"publisher","first-page":"1310309","DOI":"10.3389\/fphar.2024.1310309","volume":"15","author":"H Thirot","year":"2024","unstructured":"Thirot H, Fage D, Leonhardt A, et al. Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers. Front Pharmacol. 2024;15:1310309. https:\/\/doi.org\/10.3389\/fphar.2024.1310309.","journal-title":"Front Pharmacol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01810-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01810-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:54:18Z","timestamp":1737100458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01810-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1810"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01810-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}